Clinical and Translational Radiation Oncology · 2018 · 76 citations · 8 references
MedicineOncologyRadiation OncologyClinical Radiation OncologyOncology PharmacotherapyPalliative OncologyPalliative PharmacotherapyPalliative RadiotherapyRadiation TherapyRadiation ToxicityResponse AssessmentToxicity ManagementAtaxia Telangiectasia And Rad3-related InhibitionAtaxia-telangiectasia SignalingAtr ActivationExpansion CohortsPalliative Radiotherapy ResponsePalliative Radiotherapy ToxicityPalliative TherapyRadiotherapy Trials
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
8
Meredith A. Morgan, Leslie A. Parsels, Lili Zhao et al. · Cancer Research · 2010 · 299 citations · Full text
Medicine, Oncology, Pharmacology +13
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
Isabel M. Pires, Monica M. Olcina, Selvakumar Anbalagan et al. · British Journal of Cancer · 2012 · 168 citations · Full text
Medicine, Cancer Biology, Oncology +17
Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
Carl G. Engelke, Leslie A. Parsels, Yushen Qian et al. · Clinical Cancer Research · 2013 · 102 citations
Medicine, Oncology, Pharmacology +14